The FDA has approved the Cologuard Plus test, a next-generation, multitarget stool DNA test approved for patients at an average risk for colorectal cancer.
Next-generation CRC test earns FDA approval
The FDA has approved the Cologuard Plus test, a next-generation, multitarget stool DNA test approved for patients at an average risk for colorectal cancer.